Prostate Cancer | Specialty

Proteoglycan Assay Shows Potential as Adjunct to PSA Measurement

May 18th 2015

A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.

Sexual Function Scores Are Better After Robotic Versus Open Surgery for Prostate Cancer

May 18th 2015

Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.

Dr. Moul on Impact of Obesity in Active Surveillance

May 18th 2015

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.

Dr. O'Neil on Superior Quality of Life After Robotic Prostatectomy

May 18th 2015

Brock O'Neil, MD, physician, instructor in urologic surgery, Vanderbilt University, discusses a study that demonstrated evidence of superior quality of life after robotic assisted radical prostatectomy.

'Chilling Effect' Seen After USPSTF Recommends Against Routine PSA Testing

May 17th 2015

Since the USPSTF guideline on PSA screening the overall rate of PSA testing decreased by 50% among primary care physicians at Oregon Health & Science University.

Urine Assay Shows Promise as Test for High-Grade Prostate Cancer

May 17th 2015

A urine assay that targets expression of exosomal messenger RNA demonstrated high negative predictive value for high-grade prostate cancer in a study that validates the emerging test as a tool to help determine whether patients need initial biopsies.

Bone Metastases in CRPC: Prognostic for Survival

May 17th 2015

Biomarkers Indicative of Bone Lesions in Prostate Cancer

May 17th 2015

Asymptomatic Versus Symptomatic Bone Metastases in Prostate Cancer

May 17th 2015

Symptomatic Bone Lesions in CRPC: More Options for Treatment

May 17th 2015

Reducing Skeletal-Related Events in Prostate Cancer

May 17th 2015

Administering Radium-223 for mCRPC

May 17th 2015

Reassessing Trial Endpoints for CRPC

May 17th 2015

AUA2015: Biomarkers, Enzalutamide, and ARN509

May 17th 2015

Combining and Sequencing Sipuleucel-T in CRPC

May 17th 2015

Enzalutamide Bests Bicalutamide in Two CRPC Studies

May 17th 2015

Enzalutamide significantly improved progression-free survival, PSA kinetics, and quality of life compared with bicalutamide in men with castration-resistant prostate cancer.

Dr. Brawer on Clinical Utility of CCP Test in Prostate Cancer

May 17th 2015

Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the clinical utility of the cell cycle progression (CCP) test in personalizing prostate cancer treatment.

Active Surveillance Protocols Needed for Prostate Cancer

May 16th 2015

As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.

Multiparametric MRI Avoids Many Biopsies, Misses a Few Cancers Compared With TRUS

May 16th 2015

Use of multiparametric MRI as follow-up to a suggestive PSA test or digital rectal exam reduced prostate biopsies by 73% but identified fewer prostate cancers compared with upfront transrectal ultrasound–guided biopsy, a decision-tree analysis showed.

Dr. Crawford on LHRH Agonists and GNRH Antagonists

May 16th 2015

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado Denver, discusses the differences between an LHRH agonist and a GNRH antagonist.